Investigating Safety, Tolerability and Efficacy of AZD5363 When Combined With Paclitaxel in Breast Cancer Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced or Metastatic Breast Cancer|ER+ve Advanced or Metastatic Breast Cancer
Interventions: DRUG: AZD5363 when combined with weekly paclitaxel.|DRUG: AZD5363 when combined with weekly paclitaxel.|DRUG: AZD5363when combined with weekly paclitaxel.|DRUG: A placebo in combination with weekly paclitaxel.
Sponsor: AstraZeneca